[1]文西年,陈兵,阿不都外力·吾守尔.奥曲肽在胃肠道肿瘤所致恶性肠梗阻治疗中的应用[J].中国微创外科杂志,2011,11(5):409-420.
　Wen Xinian,Chen Bing,Abuduwaili Wushouer..Somatostatin (Octreotide) for Malignant Bowel Obstruction[J].Chinese Journal of Minimally Invasive Surgery,2011,11(5):409-420.
点击复制

奥曲肽在胃肠道肿瘤所致恶性肠梗阻治疗中的应用()
分享到：

《中国微创外科杂志》[ISSN:1009-6604/CN:11-4526/R]

卷:
11
期数:
2011年5期
页码:
409-420
栏目:
出版日期:
2011-05-20

文章信息/Info

Title:
Somatostatin (Octreotide) for Malignant Bowel Obstruction
作者:
文西年; 陈兵; 阿不都外力·吾守尔
新疆医科大学第一附属医院胃肠外科，乌鲁木齐830054
Author(s):
Wen Xinian;  Chen Bing; Abuduwaili Wushouer.
Department of Gastrointestinal Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi 830054, China
关键词:
生长抑素; 恶性肠梗阻
Keywords:
Somatostatin; Intestinal obstruction
分类号:
R574.205
文献标志码:
A
摘要:
目的探讨生长抑素类似物——奥曲肽治疗胃肠道肿瘤所致恶性肠梗阻的临床效果。方法回顾性分析2006年1月~2008年2月我院42例恶性肠梗阻的临床资料，分为奥曲肽组23例和对照组19例，比较2组患者在治疗后腹痛、腹胀症状变化，肛门恢复排气排便时间，胃肠减压量，中转手术率和住院时间。结果奥曲肽组腹胀、腹痛缓解率783%（18/23）较常规组36.8% (7/19) 有明显改善(χ2=7.409，P=0.006)；奥曲肽组胃肠引流量（409.1±32.4）ml显著少于常规组（605.7±45.9）ml(t=-16.237，P=0.000)；奥曲肽组中转手术率21.7%（5/23）显著低于常规组63.2%（12/19）(χ2=7409，P=0.006)；治疗后肛门开始排气时间奥曲肽组(4.1±1.3)d 显著短于常规组(6.5±2.7)d（t=3.773，P=0000）； 治疗后奥曲肽组生活质量明显改善，KPS评分为（61.2±7.2）分，显著高于常规组（45.1±7.8）分(t=4.910，P=0000)。结论在常规治疗基础上加用生长抑素类似物奥曲肽能改善胃肠道肿瘤所致肠梗阻患者的临床症状，降低中转手术率，改善患者生活质量。
Abstract:
ObjectiveTo investigate the effectiveness of somatostatin (octreotide) in the treatment of malignant bowel obstruction (MBO) due to gastrointestinal carcinoma.MethodsClinical data of 42 patients with MBO due to gastrointestinal carcinoma were retrospectively analyzed since January 2006 though February 2008. The patients were divided into two groups：control group (routine therapy, n=19) and octreotide group (n=23). Octreotide group received routine therapy combined with octreotide. The change of abdominal symptoms, gastrointestinal function recovery time, gastrointestinal drainage volume, the rate of conversion to open surgery, and hospital stay were observed and compared between the two groups. ResultsAfter the treatment, the abdominal distention and pain were relieved significantly in octreotide group compared to the control group ［78.3% (18/23) vs. 36.8% (7/19), χ2=7.409, P=0.006］. Furthermore, the octreotide group showed significantly less gastrointestinal drainage volume, lower rate of conversion to open surgery, shorter recovery time for gastrointestinal function, and higher KPS ［(409.1±32.4) ml vs. (605.7±45.9) ml, t=-16.237, P=0.000; 21.7% (5/23) vs. 63.2% (12/19), χ2=7.049, P=0.006; (4.1±1.3) d vs. (6.5±27) d, t=3.773, P=0.016 ; 61.2±7.2 vs. 45.1±7.8, t=4.910, P=0.000］.ConclusionsOctreotide combined with routine treatment is effective in the management of MBO. It can effectively relieve the symptoms of MBO, reduce the rate of conversion to open surgery, and improve the quality of life of patients. 　　

参考文献/References:

[1]黎介寿.认识术后早期炎症性肠梗阻的特征.中国实用外科杂志, 1998, 18(7):387-388.
[2]Oberg KE, Reubi JC, Kwekkeboom DJ, et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology， 2010， 139(3): 742-753.
[3]Chamberlain MC, Johnston SK, Glantz MJ. Neoplastic meningitisrelated prognostic significance of the Karnofsky performance status. Arch Neurol, 2009， 66(1): 74-78.
[4]李苹.生长抑素对老年急性肠梗阻患者内环境的影响.齐齐哈尔医学院学报,2009,30(24):3029-3031.
[5]Mercadante S, Casuccio A, Mangione S. Medical treatment for inoperable malignant bowel obstruction: a qualitative systematic review. J Pain Symptom Manage, 2007,33(2): 217-223.
[6] Weber C, Zulian GB. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics. Am J Hosp Palliat Care, 2009, 26(2): 84-88.
[7]沈焘, 李云峰, 蔡欣怡. 大肠癌合并恶性肠梗阻18例的非手术治疗. 实用癌症杂志, 2009,24(5): 514-516.
[8]王育红, 刘刚, 陈学东, 等. 生长抑素在恶性肠梗阻非手术治疗中的应用. 中国新药杂志,2009,18(16):1525-1527.

备注/Memo

备注/Memo:
阿不都外力·吾守尔通讯作者，Email:wy98288@medmail.com.cn
更新日期/Last Update: 2013-04-18